Total Payments
$520,081
2024 Payments
$98,481
Companies
9
Transactions
402
Medicare Patients
2,524
Medicare Billing
$384,602
Payment Breakdown by Category
Other$365,222 (70.2%)
Travel$86,752 (16.7%)
Consulting$59,140 (11.4%)
Food & Beverage$8,955 (1.7%)
Education$11.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $355,227 | 105 | 68.3% |
| Travel and Lodging | $86,752 | 141 | 16.7% |
| Consulting Fee | $59,140 | 30 | 11.4% |
| Food and Beverage | $8,955 | 122 | 1.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,620 | 1 | 0.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,410 | 1 | 0.7% |
| Grant | $1,965 | 1 | 0.4% |
| Education | $11.92 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $254,257 | 203 | $0 (2024) |
| Gilead Sciences, Inc. | $124,613 | 83 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $71,292 | 51 | $0 (2024) |
| Stemline Therapeutics Inc. | $50,242 | 42 | $0 (2024) |
| Daiichi Sankyo Inc. | $17,186 | 13 | $0 (2024) |
| Puma Biotechnology, Inc. | $2,377 | 7 | $0 (2018) |
| Genentech, Inc. | $75.00 | 1 | $0 (2023) |
| TerSera Therapeutics LLC | $22.02 | 1 | $0 (2024) |
| Genentech USA, Inc. | $17.65 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $98,481 | 68 | AstraZeneca Pharmaceuticals LP ($41,251) |
| 2023 | $98,718 | 72 | Gilead Sciences, Inc. ($42,953) |
| 2022 | $72,437 | 53 | Gilead Sciences, Inc. ($68,793) |
| 2021 | $4,910 | 5 | Novartis Pharmaceuticals Corporation ($3,275) |
| 2020 | $10,977 | 8 | Novartis Pharmaceuticals Corporation ($10,964) |
| 2019 | $124,145 | 87 | Novartis Pharmaceuticals Corporation ($124,145) |
| 2018 | $93,812 | 90 | Novartis Pharmaceuticals Corporation ($91,435) |
| 2017 | $16,602 | 19 | Novartis Pharmaceuticals Corporation ($16,602) |
All Payment Transactions
402 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,330.00 | General |
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $77.20 | General |
| Category: Oncology | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $41.08 | General |
| 12/10/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 12/10/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $75.00 | General |
| 12/03/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: Oncology | ||||||
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,340.00 | General |
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $23.35 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,020.00 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,020.00 | General |
| Category: Oncology | ||||||
| 10/18/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $3,525.00 | General |
| 10/17/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,665.00 | General |
| 10/16/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,100.00 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Travel and Lodging | In-kind items and services | $1,293.91 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Travel and Lodging | In-kind items and services | $247.85 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 10/02/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $22.10 | General |
| Category: Oncology | ||||||
| 09/30/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,020.00 | General |
| Category: Oncology | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Travel and Lodging | In-kind items and services | $1,204.07 | General |
| Category: Oncology | ||||||
| 09/25/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $120.29 | General |
| Category: Oncology | ||||||
| 09/05/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,860.00 | General |
| Category: Oncology | ||||||
| 07/23/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,350.00 | General |
| Category: ONCOLOGY | ||||||
| 07/22/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 617 | 927 | $293,165 | $95,232 |
| 2022 | 9 | 704 | 1,034 | $329,955 | $108,032 |
| 2021 | 9 | 730 | 1,082 | $316,875 | $115,960 |
| 2020 | 7 | 473 | 668 | $175,280 | $65,377 |
Total Patients
2,524
Total Services
3,711
Medicare Billing
$384,602
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 242 | 341 | $83,920 | $26,850 | 32.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 105 | 200 | $72,000 | $22,645 | 31.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 86 | 92 | $47,550 | $14,802 | 31.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 20 | 62 | $30,420 | $9,307 | 30.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 45 | 78 | $22,710 | $8,661 | 38.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 33 | 33 | $14,685 | $4,803 | 32.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 34 | 57 | $11,570 | $4,209 | 36.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 29 | 33 | $6,465 | $2,494 | 38.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 23 | 31 | $3,845 | $1,461 | 38.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 123 | 222 | $79,920 | $25,268 | 31.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 226 | 323 | $79,190 | $24,540 | 31.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 123 | 128 | $65,920 | $23,860 | 36.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 25 | 70 | $40,600 | $11,351 | 28.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 59 | 92 | $24,840 | $8,910 | 35.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 48 | 75 | $14,625 | $5,064 | 34.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 27 | 27 | $12,015 | $4,267 | 35.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 36 | 37 | $6,845 | $2,533 | 37.0% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 37 | 60 | $6,000 | $2,240 | 37.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 239 | 374 | $82,815 | $29,624 | 35.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 122 | 129 | $65,400 | $24,053 | 36.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 115 | 174 | $53,915 | $19,408 | 36.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 24 | 96 | $41,520 | $16,370 | 39.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 64 | 100 | $26,145 | $9,530 | 36.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 49 | 49 | $20,790 | $7,656 | 36.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 49 | 75 | $13,995 | $4,814 | 34.4% |
About Dr. Jules Cohen, M.D
Dr. Jules Cohen, M.D is a Hematology & Oncology healthcare provider based in Stony Brook, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/08/2008. The National Provider Identifier (NPI) number assigned to this provider is 1215112289.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jules Cohen, M.D has received a total of $520,081 in payments from pharmaceutical and medical device companies, with $98,481 received in 2024. These payments were reported across 402 transactions from 9 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($355,227).
As a Medicare-enrolled provider, Cohen has provided services to 2,524 Medicare beneficiaries, totaling 3,711 services with total Medicare billing of $384,602. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Stony Brook, NY
- Active Since 01/08/2008
- Last Updated 07/16/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1215112289
Products in Payments
- KISQALI (Drug) $224,051
- Trodelvy (Drug) $124,581
- Orserdu (Drug) $50,242
- LYNPARZA (Drug) $36,955
- ENHERTU (Biological) $24,212
- Enhertu (Drug) $17,186
- PIQRAY (Drug) $15,032
- AFINITOR (Drug) $6,047
- Nerlynx (Drug) $2,377
- Zoladex (Drug) $22.02
- TECENTRIQ (Biological) $17.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Stony Brook
Achuta Guddati, Md, MD
Hematology & Oncology — Payments: $1,873
Hematology & Oncology $1,873
Dr. Christina Lee, M.d, M.D
Hematology & Oncology — Payments: $1,111
Hematology & Oncology $1,111
Dr. Thomas Jandl, M.d, M.D
Hematology & Oncology — Payments: $601.36
Hematology & Oncology $601.36
Huda Salman, M.d, M.D
Hematology & Oncology — Payments: $532.26
Hematology & Oncology $532.26
Dr. Judy Huang, Do, DO
Hematology & Oncology — Payments: $497.15
Hematology & Oncology $497.15
Anna Andrzejczyk
Hematology & Oncology — Payments: $473.57
Hematology & Oncology $473.57